Image: kff.org · rights & removal
Executive Summary
Facts Only
* The average monthly Part D premium is estimated to increase by only $1, from $35 to $36, for most enrollees in 2027.
* The number of stand-alone PDPs available to the average beneficiary will fall from 11 in 2026 to 9 in 2027.
* PDP availability in 2027 varies by state, ranging from 8 PDPs in 15 states to 12 PDPs in 1 state.
* Enrollees in six of the eight national Part D plans continuing in 2027 will see premium reductions in some states if they keep their current plan.
* Enrollees in many other states face higher premiums for the same plans if they do not switch.
* No zero premium PDPs will be available for Part D enrollees without low-income subsidies (LIS) in 2027.
* Twenty-eight percent of PDP enrollees without LIS, or 4 million enrollees, paid no monthly premium in 2026 and will face higher premiums in 2027 regardless of plan choice.
* Specific premium increases are noted for certain plans: Humana Basic Rx PDP enrollees may face increases of $6.30 to $30.60 per month; Wellcare Value Script enrollees may face monthly increases of $5.30; and AARP Medicare Rx Saver enrollees may face an increase of $10.30 per month.
* Centene offers the lowest premiums, with 2027 monthly premiums at $5.30 for Wellcare Value Script in 45 states and $7.30 for Wellcare Classic in 33 states.
* Enrollees in United’s AARP-branded PDPs may face monthly premium increases of $50 or more in many states if they keep their current plan.
Full Take
From the original · KFF (Health Policy)
The Centers for Medicare & Medicaid Services (CMS) has just released information about Medicare Part D plans for 2027, including plan availability and premiums for the coming year. The agency emphasized stability in the Part D prescription drug plan (PDP) marketplace for 2027 (as it did for 2026) and estimated only a modest $1 increase in the average monthly PDP premium from $35 to $36.Read the full story at kff.org
Sentinel — provisional
No strong signs of machine writing were found in the source article. Provisional estimate, not a finding that a person wrote it.
The text presents complex regulatory data in a synthesized manner, showing features consistent with expert analysis rather than raw AI generation. It effectively uses figures to build an argument about risk and choice for the reader.
This looks only at the wording of the original source article, not at this page's AI-written sections. A small local AI model made this estimate. It has not been checked against known human and machine texts, so treat it as provisional. It cannot show who wrote an article.
